LRRK2 and Parkinson disease: As described above, the pathogenic LRRK2 mutation increases oxidative stress vulnerability, so PD patients with a LRRK2 mutation or iPD subjects with higher LRRK2 kinase activity may be more likely to positively respond to these treatments, taking a precision medicine-based approach.